BACKGROUND: Platelet transfusions have been identified as an independent risk factor for survival after orthotopic liver transplantation (OLT). In this study, we analyzed the specific causes of mortality and graft loss in relation to platelet transfusions during OLT. METHODS: In a series of 449 consecutive adult patients undergoing a first OLT, the causes of patient death and graft failure were studied in patients who did or did not receive perioperative platelet transfusions. RESULTS: Patient and graft survival were significantly reduced in patients who received platelet transfusions, compared with those who did not (74% vs 92%, and 69% vs 85%, respectively at 1 yr; P Ͻ 0.001). Lower survival rates in patients who received platelets were attributed to a significantly higher rate of early mortality because of acute lung injury (4.4% vs 0.4%; P ϭ 0.004). There were no significant differences in other causes of mortality between the two groups. The main cause of graft loss in patients receiving platelets was patient death with a functioning graft. CONCLUSIONS: These findings suggest that platelet transfusions are an important risk factor for mortality after OLT. The current study extends previous observations by identifying acute lung injury as the main determinant of increased mortality. The higher rate of graft loss in patients receiving platelets is related to the higher overall mortality rate and does not result from specific adverse effects of transfused platelets on the grafted liver.
as better understanding of risk factors for excessive blood loss in patients undergoing orthotopic liver transplantation (OLT), have resulted in a steady decrease in intraoperative blood loss and transfusion requirements. 1 Presently, some centers report a complete avoidance of blood product transfusions in up to 40% of liver transplant recipients. [1] [2] [3] This increasing number of patients, who do not receive any blood products during OLT, makes it possible to study potential risks and benefits of transfused blood products.
Apart from the obvious life-saving benefits, there is accumulating evidence that transfusion of blood products is associated with substantial side effects. Although, most previous studies in liver transplantation have focused on the impact of red blood cell (RBC) transfusions, 4, 5 platelet transfusions have also been identified as an independent risk factor for postoperative morbidity and mortality. 6, 7 This negative impact is independent from well-accepted indices of severity of disease, such as the model of end-stage liver disease (MELD) score and Karnofsky score, and similar to well-described adverse effects of platelet transfusions in patients undergoing cardiac surgery. 7 The specific cause of increased mortality in liver transplant patients who receive platelet transfusion, however, has not been examined.
The major complications of transfusion are infectious and immunologic. 8 -10 Although the risk of viral transmission (e.g., human immunodeficiency virus and cytomegalo virus) is well known, this risk has decreased substantially during the last decade because of improved donor screening and virus-inactivating procedures. 11 Transfusion-related morbidity and mortality because of bacterial contamination, however, remain a concern, especially for platelets which are stored at room temperature. 8 Transfusion-related immunological adverse effects include alloimmunization, anaphylactic reactions, hemolysis, graft versus host disease, and nonspecific immunosuppressive effects. In addition, blood product transfusions have been identified as a risk factor for transfusion-related acute lung injury (TRALI). 8, 12 Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening disorders characterized by severe inflammation of the lungs. 13 The risk of developing ALI/ARDS seems to be higher after transfusion of fresh frozen plasma (FFP) or platelets than after RBC transfusion. 14 Although platelet transfusions have been identified as a risk factor for reduced graft and patient survival after OLT, no previous studies addressed mechanism. The aim of this study was to evaluate the specific causes of graft loss and patient mortality in patients who received platelet transfusion during OLT versus those who did not.
METHODS

Patients
Eight hundred three liver transplantations were performed in our center between January 1, 1989 and December 31, 2005 . After excluding pediatric transplants (age Ͻ18 yr; n ϭ 252), retransplantations (n ϭ 90) and combined organ transplantations (n ϭ 12), 449 adult patients undergoing a first OLT formed the basis of the current study. Analysis of this same patient population 6 previously showed that intraoperative platelet transfusion is associated with increased mortality after OLT.
Characteristics of these patients, including donor and recipient variables, as well as surgical factors were obtained from a prospectively maintained computer database. When necessary, the original patient notes were reviewed for missing information. Individual patients were not identifiable in the database. National legislation and the ethical committee of our institution approved this retrospective study.
Surgical Techniques and Perioperative Care
ABO group identical or compatible grafts from donation after brain death and cardiac death were used for all patients. In the study period, both the conventional technique for OLT and the cava-sparing piggyback technique were used for implantation. 15 The piggyback technique was first performed in our center in 1994, and it has become the preferred surgical technique in the vast majority of patients since 1997. 16 Before 1997, venovenous bypass was used in most cases of conventional OLT, yet in recent years it has not been used in combination with the piggyback technique.
Anesthesia was initially maintained with a total IV technique using sufentanil, midazolam, and vecuronium, and volume-controlled ventilation. (Midazolam has gradually been replaced by isoflurane). Blood loss was compensated for by transfusion of allogeneic RBC to maintain the hematocrit between 0.25 and 0.30. In addition, a cell saver device (Hemonetics, Braintree, MA) was used in selected patients, when excessive blood loss was anticipated. Other blood products, such as FFP and platelets, were only given in the presence of significant blood loss and never solely dictated by laboratory values. Platelet concentrates were given if the platelet count decreased below 50 ϫ 10 9 /L, only in the presence of diffuse bleeding. One unit of platelet concentrates contained approximately 150 mL and was obtained from five random donors. Aprotinin was administered in all patients, except patients with known thrombophilia or preexisting thrombotic conditions, or signs of hypercoagulability on thrombelastography at the time of induction of anesthesia. Based on evolving scientific evidence concerning the efficacy of aprotinin, guidelines have been slightly adapted during the study period. 17 
Patient and Graft Survival
Graft survival was assessed at 90 days and at 1 yr after transplantation and was defined as the time period between transplantation and patient death or retransplantation. Patient survival was also assessed at 90 days and 1 yr after transplantation and was defined as the time period between transplantation and patient death.
Causes of graft loss were grouped into the following categories: primary nonfunction, hepatic artery thrombosis, portal vein thrombosis, hepatic vein thrombosis, biliary complications (such as nonanastomotic biliary strictures or recurrent cholangitis), acute or chronic rejection, and patient death. In addition, the following causes of patient death were identified: graft failure, cardiovascular disease (including myocardial infarction and hypovolemic shock), pulmonary complications (including ALI or ARDS and pulmonary embolism), central nervous system complications (including ischemic and hemorrhagic stroke), sepsis or multiple organ failure, and malignancy.
ALI and ARDS were diagnosed using criteria of the American-European Consensus Conference. 18 
Statistical Analysis
Continuous variables are reported as medians with ranges and categorical variables as numbers with percentages. Categorical variables were compared using the Pearson 2 test or Fisher's exact test. A comparison of continuous variables was performed using the Mann-Whitney U-test. Odds ratios and 95% confidence intervals were calculated using logistic regression analysis. Survival curves were calculated according to the Kaplan-Meier method and compared using the log-rank test. A two-tailed P value of Ͻ0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 14.0 (SPSS, Chicago, IL).
RESULTS
Patient Characteristics
Patient, donor, and surgical characteristics, as well as preoperative laboratory values for the entire group of 449 patients, are summarized in Table 1 . The minimal postoperative follow-up was 12 mo for each patient and median follow-up was 111 mo (range 14 -217 mo). Overall patient and graft survival rates at 1 yr were 85% and 79%, respectively.
Impact of Platelet Transfusions During OLT on Outcome
The median (range) requirement of platelet transfusions for the entire study group was 0 U (range 0 -1 (Table 1 ). In an univariate analysis for platelet transfusions, patients who received platelet transfusions during OLT had a higher MELD score, a lower Karnofsky score, higher blood loss, received more RBC and FFP transfusions during OLT and did have worse preoperative laboratory values. Furthermore, longer and colder ischemia times were associated with patients who received platelets during OLT (Table 1) . A statistically significant stepwise reduction in both patient and graft survival rates was observed with increasing number of platelet transfusions. Patients who received platelets had reduced survival early after transplantation (within 90 days) compared with those who did not receive platelets, with no difference in survival after that time period. Therefore, for further analysis, we focused on determinants of early death or graft loss within 90 days after transplantation.
According to institutional guidelines, platelet transfusions were only given to patients who suffered excessive blood loss and had low platelet counts (Ͻ50,000 ϫ 10 9 /L). We, therefore, examined whether the lower survival rate in patients receiving platelets could be explained by the fact that these patients had more blood loss or lower preoperative platelet counts (and thus were sicker). Patients who received platelet transfusions were indeed found to have significantly lower patient and graft survival rates than patients who suffered excessive blood loss (requiring Ͼ6 U of RBC) without platelet transfusions (Fig. 1) . In addition, patients who received platelets had significantly lower patient and graft survival rates than patients who had a preoperative platelet count below 50 ϫ 10 9 /L, but who did not receive platelet transfusions (Fig. 2) . These findings indicate that the negative association between platelet transfusion and survival is not simply related to the fact the patients receiving platelet transfusions had lower preoperative platelet counts or suffered greater intraoperative blood loss.
Cause of Increased Patient Death After Platelet Transfusion
To determine the cause of increased mortality in patients receiving platelets during OLT, the specific causes of death in the two groups were compared. Death because of ALI/ARDS occurred more frequently in patients who received platelets (Odds ratio 12.23; 95% confidence interval, 1.51-98.64; P ϭ 0.004) ( Table 2 ). Eight patients who received intraoperative platelet transfusions died from ALI/ARDS. In three of these patients, postmortem autopsy was performed, showing heavy lungs because of severe lung edema in accordance with the clinical diagnosis of ARDS. All other causes of death were similarly distributed. When comparing the characteristics of the patients with early mortality because of ALI/ARDS with those who died from other causes, no other significant differences were found. In particular, preoperative platelet count and intraoperative blood loss were not different in patients who died from ARDS, compared with those who died from other causes ( Table 3 ).
Causes of Graft Loss in Relation to Platelet Transfusions
To determine the cause of graft loss in patients who received platelets, we compared the specific causes of graft loss in patients who received platelets with those who did not (Table 4 ). Patient death with a functioning graft appeared to be the most frequent overall cause of graft loss. Early graft loss because of patient death occurred significantly more frequently in patients who received platelets, compared with those who did not. There were no significant differences in the distribution of the other causes of early graft loss between the two groups.
DISCUSSION
Platelet transfusions have been identified as an independent risk factor for adverse postoperative outcome after cardiac surgery and liver transplantation. 6, 7 Our group recently reported that intraoperative platelet transfusions are an independent risk factor for 1-yr patient survival after liver transplantation. Multivariate analysis revealed no significant negative impact of platelet transfusion on graft survival. 6 The present study extends this report and shows that decreased survival of patients as a function of platelet transfusion is due to a higher rate of ALI or ARDS. The increased rate of graft loss after platelet transfusions was not related to graft-related thrombotic complications, such as hepatic artery thrombosis, but caused by higher patient mortality with a functioning graft.
The findings of our study indicate that the adverse effects of platelet transfusions are due to a more systemic response. Transfusion of blood products can cause severe pulmonary reactions, also known as TRALI or ARDS. 19 TRALI/ARDS is the leading cause of transfusion-related death because in 5%-15% of these cases this reaction is fatal. 19, 20 Although massive RBC transfusion has long been implicated as a risk factor for TRALI/ARDS, recent studies show that not RBC, but, in fact, plasma-rich blood products, such as FFP and platelet transfusions, are associated with the development of ALI/ARDS. 14 This is in line with two leading hypotheses for pathogenesis of TRALI/ARDS: passive transfer of antileukocyte antibodies in plasmarich blood products as platelets, 8, 21 and the accumulation of inflammatory mediators in stored platelets. 22 In our study, the risk of developing TRALI/ARDS was higher in patients who received platelet transfusions during liver transplantation in comparison with other blood products.
ALI and ARDS are clinical syndromes characterized by the acute onset of severe hypoxemia and bilateral pulmonary infiltrates in the absence of clinical evidence for left atrial hypertension. 13, 23 Both ALI and ARDS occur in association with a variety of clinical disorders, including sepsis, pneumonia, aspiration, trauma, including inhalational injury, and (massive) blood transfusions (TRALI). The hallmark of ALI/ARDS is diffuse alveolar damage and increased pulmonary microvascular permeability with increased protein content of the edema fluid. 13, 23 Two putative mechanisms explaining the increased pulmonary microvascular permeability have been proposed: 1) binding of cytotoxic leukocyte antibodies causing complement activation 21 and 2) neutrophil-priming activity of biologically active substances, such as lipids or cytokines. 22 Both effects cause endothelial damage and capillary leakage resulting in ALI. Next to leukocytes and erythrocytes, platelets may play a role in enhancing lung endothelial injury in concert with cytokines-releasing leukocytes. 13, 21, 22, 24 Pulmonary platelet sequestration has also been implicated in the pathophysiology of ALI/ARDS. 23, 25 The cause of platelet aggregation, however, is unclear and different hypotheses have been described in liver transplant recipients, including pulmonary aggregation of platelets because of cell debris released from the ischemic donor liver, 26, 27 or by the release of endotoxins from the donor liver after reperfusion. 28 Transfused platelets have been suggested as a possible cause of multiple platelet emboli in the lung. 29, 30 Platelet microaggregates formed in stored platelet concentrates may obstruct small pulmonary vessels and therefore lead to ALI/ARDS. Platelet concentrates can be stored for up to 5 days at room temperature. Storage for several days results in platelet activation accompanied by release of growth factors and cytokines from platelet granules, as well as conjugation with white blood cells. Cytokine levels in the medium of platelet concentrates can increase as high as 1000-fold compared with the plasma levels seen in normal healthy individuals. In that way, a platelet transfusion itself is proinflammatory and a risk factor for the development of TRALI/ARDS. 31 Storage at room temperature makes platelet concentrates prone to bacterial contamination. Bacterial infection or sepsis may lead to activation of leukocytes and subsequent priming and sequestration of leukocytes into the lungs, which is a serious risk factor for TRALI/ARDS. 19 Unfortunately, we had no information on the storage times of blood platelet concentrates given to the individual patients in our study. Platelet concentrates are prepared by using either one of the two whole-blood procedures (platelet-rich plasma or buffy coat based) or by using plateletpheresis. 9 Both the platelet-rich plasma and buffy coat procedures use a two-step differential centrifugation process. Plateletpheresis is done by blood-cell separators that allow the selective collection of large numbers of platelets in predefined volumes of donor plasma. Only one donor is used for platelet concentrates prepared by plateletpheresis, whereas platelet concentrates prepared from whole blood use pooled material from four to eight donors. Although plateletpheresis is more expensive, the fewer donors to which recipients are exposed decreases the risk of transfusion-related complications. 32 In the current study, all platelet concentrates were prepared by the buffy coat-based procedure, in which platelets from five donors were pooled for 1 U of platelets. The increased rate of early postoperative death because of ALI/ARDS may have been related to the preparation procedure used, but based on our data we cannot make conclusions on the impact of the preparation method.
Although platelet transfusions in liver transplantation appear to be a risk factor for decreased patient survival after liver transplantation because of ALI/ARDS, it is difficult to prove causality in a retrospective analysis. Platelet transfusions might be a surrogate marker for sicker patients. When comparing recipient, donor, and transplantation characteristics for patients who did and patients who did not receive platelet transfusions during liver transplantation, patients receiving platelet transfusion had a higher MELD score, a lower Karnofsky score, higher blood loss, received more FFP and RBC transfusions during liver transplantation, were associated with longer cold and warm ischemia times, and had worse preoperative laboratory values. All these variables indicate that patients who received platelets during liver transplantation were sicker. However, in our previous study on the same cohort used here, we already showed that patient survival rates were independently associated with platelet transfusions during liver transplantation. 6 Furthermore, the suggestion can be made that patients who received platelets during liver transplantation suffered from lower preoperative platelet counts or greater intraoperative blood loss and thus were sicker. When calculating survival rates in patients with greater intraoperative blood loss and lower preoperative platelet counts who did and did not receive platelets during liver transplantation, survival was significant lower in those patients who received platelets in comparison with those who did not. Actually, survival rates in patients who had low preoperative platelet counts and high intraoperative blood loss, but who did not receive any platelet concentrates, were similar to survival rates in the reference population (patients with normal preoperative platelet count and no major blood loss). These findings indicate that the negative association between platelet transfusion and survival is not simply related to the fact that patients receiving platelet transfusions were sicker, or had lower preoperative platelet counts and/or high intraoperative blood loss. Definite proof, however, could only come from prospective, randomized, controlled studies in which different thresholds for platelet transfusions are compared. Although prospective trials comparing different platelet thresholds as a trigger for platelet transfusions have been performed in patients suffering from leukemia, 33 to our knowledge, such studies have never been performed in liver transplant recipients. Ethical consideration, and the large variation in platelet function and thrombocytopenia in these patients, will make this kind of study very difficult to perform. Despite the lack of randomized studies, our findings are in agreement with previous studies in and outside the field of liver transplantation, and provide substantial support for the hypothesis that platelet transfusions are a risk factor for ALI/ARDS influencing outcome after liver transplantation.
Based on this hypothesis, more rational platelet transfusion regimens are urgently needed. Triggers for platelet transfusion in liver transplant recipients should not just be based on platelet counts alone. Although a minimum number of platelets are probably required for normal hemostasis, it remains to be established at which threshold platelets should be transfused. Recent studies focusing on primary hemostasis in patients with cirrhosis have suggested that the highly elevated levels of von Willebrand Factor in these patients compensate for the reduced platelet number and primary hemostasis may not be as abnormal as would be expected based on platelet count alone. 34, 35 Laboratory tests that measure overall coagulation function in whole blood samples, such as thrombelastography, seem more appropriate to distinguish patients who may require platelet transfusion than measurement of platelet count alone. 36 -38 In addition, it seems relevant to distinguish between prophylactic platelet transfusion (i.e., platelet count under a certain threshold, without bleeding complications) and transfusions intended to control bleeding. Given the detrimental effects of platelet transfusions, it seems reasonable not to transfuse patients based on a low platelet count alone (as long as perioperative hemostasis is secured), and only to transfuse if bleeding complications do occur. It may, however, be difficult to assess whether a bleeding complication during liver transplantation is a result of the lack of (functional) platelets, is due to defects in other hemostatic systems, or has a surgical origin. An emerging new strategy to avoid platelet transfusion may be the preprocedural stimulation of platelet synthesis by a thrombopoietin-receptor agonist. 39 A possible concern, however, may be the induction of thrombo-embolic complications when platelet counts are normalized in patients with cirrhosis who usually have very high levels of von Willebrand Factor. 34, 35 In conclusion, this study confirms and extends previous hypotheses regarding the negative effects of platelet transfusions on outcome after OLT. Increased postoperative mortality in patients receiving platelets is ascribed to an increased mortality because of ALI/ARDS. Platelet transfusions were not associated with an increased occurrence of graft-related thrombotic complications. Although there is no good alternative therapy for platelet transfusions in the situation of excessive bleeding, it seems advisable to avoid unnecessary prophylactic transfusion of platelets in liver transplant recipients.
